Experimental virus therapy tested for Hard-to-Treat breast cancer

NCT ID NCT05376527

First seen May 04, 2026 · Last updated May 05, 2026 · Updated 2 times

Summary

This early-phase study tested a new drug made from a modified virus in 34 women with advanced breast cancer that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the highest dose that doesn't cause severe side effects. The drug was injected directly into tumors, first as a single dose and then weekly for four weeks. This is not a cure; it aims to control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCOLYTIC VIROTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation

    Moscow, Russia, 115478, Russia

  • N.N. Petrov National Medical Research Center of Oncology

    Saint Petersburg, Russia, 197758, Russia

  • National Medical Research Radiological Centre (NMRRC) of the Ministry of Health of the Russian Federation

    Obninsk, Russia, 249036, Russia

  • Oncology Research Center, LLC

    Saint Petersburg, Russia, 197758, Russia

Conditions

Explore the condition pages connected to this study.